Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA (2016 - 2025)

Historic EBITDA for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$31.0 million.

  • Vanda Pharmaceuticals' EBITDA fell 18730.53% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.0 million, marking a year-over-year decrease of 22767.25%. This contributed to the annual value of -$39.8 million for FY2024, which is 20509.52% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' EBITDA is -$31.0 million, which was down 18730.53% from -$38.2 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBITDA ranged from a high of $12.7 million in Q2 2021 and a low of -$40.8 million during Q1 2025
  • Over the past 5 years, Vanda Pharmaceuticals' median EBITDA value was -$5.8 million (recorded in 2023), while the average stood at -$5.9 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' EBITDA surged by 462831.86% in 2021, and later tumbled by 49342.05% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBITDA stood at $9.0 million in 2021, then decreased by 23.27% to $6.9 million in 2022, then plummeted by 199.65% to -$6.9 million in 2023, then plummeted by 45.41% to -$10.0 million in 2024, then crashed by 209.3% to -$31.0 million in 2025.
  • Its EBITDA was -$31.0 million in Q3 2025, compared to -$38.2 million in Q2 2025 and -$40.8 million in Q1 2025.